Johnson & Johnson News - July 24, 2026
Johnson & Johnson's Oral Psoriasis Drug 'Icotyde' Recommended for EU Approval
A key committee of the European Medicines Agency (EMA) recommended marketing authorization for Johnson & Johnson's new drug, Icotyde. The Committee for...
Johnson & Johnson Myeloma Combo Cuts Progression Risk 89% in Phase 3
Johnson & Johnson reported positive topline results from the Phase 3 MonumenTAL-6 study for multiple myeloma. The trial evaluated a dual-antigen regimen...
Judge Casts Doubt on Evidence in 69,000 J&J Talc Lawsuits
A U.S. federal judge has raised significant doubts about the scientific evidence underpinning approximately 69,000 lawsuits alleging Johnson & Johnson's talc...